American Type Culture Collection (ATCC) Logo American Type Culture Collection (ATCC) Logo 0
  • Quick Order
  • Careers
  • Support

Episode 24: The Convergence of Frontiers

Featuring Dr. Jesse Boehm

 

Listen on Apple Podcasts button Listen on YoutUbe Music button Listen on Spotify button Listen on Pandora button

Show Notes:

Join in, to hear Dr Jesse Boehm discuss the convergence of advancements that are making precision medicine more effective for a larger percentage of patients. He touches on how access to molecular profiling has become more widespread and affordable, allowing more patients to get detailed molecular information about their tumors. Dr. Boehm then mentions how new types of chemistry and drug development are making it possible to target a wider range of cancer proteins. He goes on to describe how innovations in biopsies enable real-time monitoring of tumors, providing a comprehensive molecular portrait of the tumor’s evolution. Overall, Dr. Boehm is optimistic that these and the other advancements that he discusses will significantly improve the outcome for most cancer patients within the next few decades.

Guest:

Jesse Boehm.jfif

Jesse Boehm, PhD

Chief Science Officer, Break Through Cancer

Jesse Boehm is the Chief Science Officer of Break Through Cancer and maintains a research lab focused on bringing the power of functional genomics to bear on living samples from cancer patients with particular emphasis on rare and underrepresented tumors. Before joining Break Through Cancer, Jesse spent 14 years in the Broad Institute’s Cancer Program, most recently as an Institute Scientist and Scientific Director of the Cancer Dependency Map project. As the Director of the Broad’s Cancer Model Development Center (part of the National Cancer Institute’s Human Cancer Models Initiative), he led his laboratory in developing a scalable capacity to convert patient tumors into organoids and other cell models. Prior, he was the recipient of a Broad Institute Merkin Fellowship and the Associate Director of the Broad’s Cancer Program. In these leadership roles, he drove the scientific planning and strategic execution of a diverse set of program projects, collaborations, and activities for over a decade. Jesse received his BS in biology from MIT and his PhD from Harvard University, Division of Medical Sciences at Dana-Farber Cancer Institute.

Host:

David Yarmosh, headshot.

David Yarmosh, MS

Lead Bioinformatician, ATCC

David Yarmosh is a lead bioinformatician in ATCC’s Sequencing and Bioinformatics Center. He’s a graduate of New York University’s Tandon School of Engineering. He has been working in large data aggregation and analysis since 2013 and microbial genomics with a focus on biosurveillance R&D efforts since 2016. David has led international training exercises in Peru and Senegal, sharing metagenomic analytical capabilities. His interests include genomics database construction, metadata collection, drug resistance mechanisms, bioinformatics standards, and machine learning. Since joining ATCC in 2020, David has worked extensively in SARS-CoV-2 classification, epidemiology, and genomics evaluation, including enhanced and uniform variant reporting. He has contributed more broadly to genomics reporting and analytical standardization and he has helped develop the podcast Behind the Biology, which he now hosts.

Advanced cell models

ATCC Organoids

ATCC provides organoids isolated from multiple organs including colon, small intestine, stomach, breast, esophagus, lung, liver, prostate, and pancreas. Discover their advantages over existing cancer models.

Discover more

HCMI Cancer Models

We are continually adding 2-D and 3-D patient-derived cancer models to our portfolio. These next-generation models include both common as well as rare and understudied examples of cancer from numerous tissues.

New HCMI products